BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parrot L, Dong C, Carbonnel F, Meyer A. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther 2021. [PMID: 34854100 DOI: 10.1111/apt.16714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Blesl A, Petritsch W, Binder L, Fürst S, Wenzl H, Baumann-Durchschein F, Kump P, Högenauer C. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study. Scand J Gastroenterol 2022;:1-4. [PMID: 35732583 DOI: 10.1080/00365521.2022.2088248] [Reference Citation Analysis]
2 McDonald BD, Dyer EC, Rubin DT. IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis 2022;16:ii42-53. [PMID: 35553664 DOI: 10.1093/ecco-jcc/jjac038] [Reference Citation Analysis]
3 Amiot A, Seksik P, Reimund J, Nachury M, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L, Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, Abitbol V, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-biroulet L, Bouguen G, Amiot A, Gagniere C, Nachury M, Wils P, Bouhnik Y, Stefanescu C, Treton X, Martins C, Uzzan M, Serrero M, Guillo L, Roblin X, Tedesco ED, Beaugerie L, Seksik P, Bourrier A, Landmann C, Kirchgesner J, Sokol H, Buisson A, Nancey S, Boschetti G, Gay C, Danion P, Flourié B, Abitbol V, Malamut G, Reimund J, Caron B, Vuitton L, Peyrin-biroulet L, Zallot C, Gilletta C, Allez M, Gornet J, Baudry C, Viennot S, Bourreille A, Trang-poisson C, Boualit M, Painchart C, Plastaras L, Altwegg R, Boivineau L, Fumery M, Laharie D, Riviere P, Poullenot F, Coffin B, Duboc H, Nahon S, Simon M, Coulibaly B, Chanteloup E, Fotsing G. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.011] [Reference Citation Analysis]